Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma

Avelumab, a human anti–programmed death ligand 1 immunoglobulin G1 antibody, has shown efficacy and manageable safety in multiple tumors. A two‐compartment population pharmacokinetic model for avelumab incorporating intrinsic and extrinsic covariates and time‐varying clearance (CL) was identified ba...

Full description

Saved in:
Bibliographic Details
Published in:CPT: pharmacometrics and systems pharmacology 2019-06, Vol.8 (6), p.415-427
Main Authors: Wilkins, Justin J., Brockhaus, Brigitte, Dai, Haiqing, Vugmeyster, Yulia, White, Joleen T., Brar, Satjit, Bello, Carlo L., Neuteboom, Berend, Wade, Janet R., Girard, Pascal, Khandelwal, Akash
Format: Article
Language:English
Subjects:
Bladder cancer
Clinical trials
Employees
Gastric cancer
Immunoglobulins
Immunotherapy
Medical prognosis
Metastasis
Monoclonal antibodies
Pharmacokinetics
Population
Skin cancer
Targeted cancer therapy
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5146-d56cb5067121bbcd2aecd687a8d709065d81ae33dc73245e387a748342e36e503
cites cdi_FETCH-LOGICAL-c5146-d56cb5067121bbcd2aecd687a8d709065d81ae33dc73245e387a748342e36e503
container_end_page 427
container_issue 6
container_start_page 415
container_title CPT: pharmacometrics and systems pharmacology
container_volume 8
creator Wilkins, Justin J.
Brockhaus, Brigitte
Dai, Haiqing
Vugmeyster, Yulia
White, Joleen T.
Brar, Satjit
Bello, Carlo L.
Neuteboom, Berend
Wade, Janet R.
Girard, Pascal
Khandelwal, Akash
description Avelumab, a human anti–programmed death ligand 1 immunoglobulin G1 antibody, has shown efficacy and manageable safety in multiple tumors. A two‐compartment population pharmacokinetic model for avelumab incorporating intrinsic and extrinsic covariates and time‐varying clearance (CL) was identified based on data from 1,827 patients across three clinical studies. Of 14 tumor types, a decrease in CL over time was more notable in metastatic Merkel cell carcinoma and squamous cell carcinoma of the head and neck, which had maximum decreases of 32.1% and 24.7%, respectively. The magnitude of reduction in CL was higher in responders than in nonresponders. Significant covariate effects of baseline weight, baseline albumin, and sex were identified on both CL and central distribution volume. Significant covariate effects of black/African American race, C‐reactive protein, and immunogenicity were found on CL. None of the covariate or time‐dependent effects were clinically important or warranted dose adjustment.
doi_str_mv 10.1002/psp4.12406
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_15698363073445438b2f4a3bd6accacf</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_15698363073445438b2f4a3bd6accacf</doaj_id><sourcerecordid>2265775722</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5146-d56cb5067121bbcd2aecd687a8d709065d81ae33dc73245e387a748342e36e503</originalsourceid><addsrcrecordid>eNp9kstuEzEUhkcIRKvSDQ-ALLFDSvHdkw1SFW6RiojUlq11xnMmcTozDvakqDvWrHhGngQnU6p0gxe25f_TZx_5FMVLRs8YpfztJm3kGeOS6ifFMWdaTEpB9dOD_VFxmtKa5mEkZVP6vDgSdFpSWbLj4teV7_DPz9_fIN75fklmLUKE3iGBvibzbgNuIKEh731CSEguBxiQhJ4MKySLFcQOXLjxPQ7epR14fovttoOK-J58wXiDLZlhmyeIzvehg734OoYsaD0cBC-KZw20CU_v15Pi-uOHq9nnycXXT_PZ-cXEKSb1pFbaVYpqwzirKldzQFfr0kBZGzqlWtUlAxSidkZwqVDkyMhSSI5Co6LipJiP3jrA2m6i73LtNoC3-4MQlxZiLqdFy5SelkILaoSUSoqy4o0EUdUanAPXZNe70bXZVh3WDvshQvtI-jjp_couw63VmplSiSx4fS-I4fsW02DXYRv7XL_lXCtjlOE8U29GysWQUsTm4QZG7a4N7K4N7L4NMvzq8E0P6L9PzwAbgR--xbv_qOziciFH6V8uX74w</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2265775722</pqid></control><display><type>article</type><title>Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><source>Wiley Open Access</source><creator>Wilkins, Justin J. ; Brockhaus, Brigitte ; Dai, Haiqing ; Vugmeyster, Yulia ; White, Joleen T. ; Brar, Satjit ; Bello, Carlo L. ; Neuteboom, Berend ; Wade, Janet R. ; Girard, Pascal ; Khandelwal, Akash</creator><creatorcontrib>Wilkins, Justin J. ; Brockhaus, Brigitte ; Dai, Haiqing ; Vugmeyster, Yulia ; White, Joleen T. ; Brar, Satjit ; Bello, Carlo L. ; Neuteboom, Berend ; Wade, Janet R. ; Girard, Pascal ; Khandelwal, Akash</creatorcontrib><description>Avelumab, a human anti–programmed death ligand 1 immunoglobulin G1 antibody, has shown efficacy and manageable safety in multiple tumors. A two‐compartment population pharmacokinetic model for avelumab incorporating intrinsic and extrinsic covariates and time‐varying clearance (CL) was identified based on data from 1,827 patients across three clinical studies. Of 14 tumor types, a decrease in CL over time was more notable in metastatic Merkel cell carcinoma and squamous cell carcinoma of the head and neck, which had maximum decreases of 32.1% and 24.7%, respectively. The magnitude of reduction in CL was higher in responders than in nonresponders. Significant covariate effects of baseline weight, baseline albumin, and sex were identified on both CL and central distribution volume. Significant covariate effects of black/African American race, C‐reactive protein, and immunogenicity were found on CL. None of the covariate or time‐dependent effects were clinically important or warranted dose adjustment.</description><identifier>ISSN: 2163-8306</identifier><identifier>EISSN: 2163-8306</identifier><identifier>DOI: 10.1002/psp4.12406</identifier><identifier>PMID: 30980481</identifier><language>eng</language><publisher>United States: John Wiley &amp; Sons, Inc</publisher><subject>Bladder cancer ; Clinical trials ; Employees ; Gastric cancer ; Immunoglobulins ; Immunotherapy ; Medical prognosis ; Metastasis ; Monoclonal antibodies ; Pharmacokinetics ; Population ; Skin cancer ; Targeted cancer therapy ; Tumors</subject><ispartof>CPT: pharmacometrics and systems pharmacology, 2019-06, Vol.8 (6), p.415-427</ispartof><rights>2019 The Authors published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.</rights><rights>2019 The Authors CPT: Pharmacometrics &amp; Systems Pharmacology published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics.</rights><rights>2019. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5146-d56cb5067121bbcd2aecd687a8d709065d81ae33dc73245e387a748342e36e503</citedby><cites>FETCH-LOGICAL-c5146-d56cb5067121bbcd2aecd687a8d709065d81ae33dc73245e387a748342e36e503</cites><orcidid>0000-0002-7099-9396</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2265775722/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2265775722?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30980481$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wilkins, Justin J.</creatorcontrib><creatorcontrib>Brockhaus, Brigitte</creatorcontrib><creatorcontrib>Dai, Haiqing</creatorcontrib><creatorcontrib>Vugmeyster, Yulia</creatorcontrib><creatorcontrib>White, Joleen T.</creatorcontrib><creatorcontrib>Brar, Satjit</creatorcontrib><creatorcontrib>Bello, Carlo L.</creatorcontrib><creatorcontrib>Neuteboom, Berend</creatorcontrib><creatorcontrib>Wade, Janet R.</creatorcontrib><creatorcontrib>Girard, Pascal</creatorcontrib><creatorcontrib>Khandelwal, Akash</creatorcontrib><title>Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma</title><title>CPT: pharmacometrics and systems pharmacology</title><addtitle>CPT Pharmacometrics Syst Pharmacol</addtitle><description>Avelumab, a human anti–programmed death ligand 1 immunoglobulin G1 antibody, has shown efficacy and manageable safety in multiple tumors. A two‐compartment population pharmacokinetic model for avelumab incorporating intrinsic and extrinsic covariates and time‐varying clearance (CL) was identified based on data from 1,827 patients across three clinical studies. Of 14 tumor types, a decrease in CL over time was more notable in metastatic Merkel cell carcinoma and squamous cell carcinoma of the head and neck, which had maximum decreases of 32.1% and 24.7%, respectively. The magnitude of reduction in CL was higher in responders than in nonresponders. Significant covariate effects of baseline weight, baseline albumin, and sex were identified on both CL and central distribution volume. Significant covariate effects of black/African American race, C‐reactive protein, and immunogenicity were found on CL. None of the covariate or time‐dependent effects were clinically important or warranted dose adjustment.</description><subject>Bladder cancer</subject><subject>Clinical trials</subject><subject>Employees</subject><subject>Gastric cancer</subject><subject>Immunoglobulins</subject><subject>Immunotherapy</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Pharmacokinetics</subject><subject>Population</subject><subject>Skin cancer</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>2163-8306</issn><issn>2163-8306</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9kstuEzEUhkcIRKvSDQ-ALLFDSvHdkw1SFW6RiojUlq11xnMmcTozDvakqDvWrHhGngQnU6p0gxe25f_TZx_5FMVLRs8YpfztJm3kGeOS6ifFMWdaTEpB9dOD_VFxmtKa5mEkZVP6vDgSdFpSWbLj4teV7_DPz9_fIN75fklmLUKE3iGBvibzbgNuIKEh731CSEguBxiQhJ4MKySLFcQOXLjxPQ7epR14fovttoOK-J58wXiDLZlhmyeIzvehg734OoYsaD0cBC-KZw20CU_v15Pi-uOHq9nnycXXT_PZ-cXEKSb1pFbaVYpqwzirKldzQFfr0kBZGzqlWtUlAxSidkZwqVDkyMhSSI5Co6LipJiP3jrA2m6i73LtNoC3-4MQlxZiLqdFy5SelkILaoSUSoqy4o0EUdUanAPXZNe70bXZVh3WDvshQvtI-jjp_couw63VmplSiSx4fS-I4fsW02DXYRv7XL_lXCtjlOE8U29GysWQUsTm4QZG7a4N7K4N7L4NMvzq8E0P6L9PzwAbgR--xbv_qOziciFH6V8uX74w</recordid><startdate>201906</startdate><enddate>201906</enddate><creator>Wilkins, Justin J.</creator><creator>Brockhaus, Brigitte</creator><creator>Dai, Haiqing</creator><creator>Vugmeyster, Yulia</creator><creator>White, Joleen T.</creator><creator>Brar, Satjit</creator><creator>Bello, Carlo L.</creator><creator>Neuteboom, Berend</creator><creator>Wade, Janet R.</creator><creator>Girard, Pascal</creator><creator>Khandelwal, Akash</creator><general>John Wiley &amp; Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-7099-9396</orcidid></search><sort><creationdate>201906</creationdate><title>Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma</title><author>Wilkins, Justin J. ; Brockhaus, Brigitte ; Dai, Haiqing ; Vugmeyster, Yulia ; White, Joleen T. ; Brar, Satjit ; Bello, Carlo L. ; Neuteboom, Berend ; Wade, Janet R. ; Girard, Pascal ; Khandelwal, Akash</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5146-d56cb5067121bbcd2aecd687a8d709065d81ae33dc73245e387a748342e36e503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Bladder cancer</topic><topic>Clinical trials</topic><topic>Employees</topic><topic>Gastric cancer</topic><topic>Immunoglobulins</topic><topic>Immunotherapy</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Pharmacokinetics</topic><topic>Population</topic><topic>Skin cancer</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wilkins, Justin J.</creatorcontrib><creatorcontrib>Brockhaus, Brigitte</creatorcontrib><creatorcontrib>Dai, Haiqing</creatorcontrib><creatorcontrib>Vugmeyster, Yulia</creatorcontrib><creatorcontrib>White, Joleen T.</creatorcontrib><creatorcontrib>Brar, Satjit</creatorcontrib><creatorcontrib>Bello, Carlo L.</creatorcontrib><creatorcontrib>Neuteboom, Berend</creatorcontrib><creatorcontrib>Wade, Janet R.</creatorcontrib><creatorcontrib>Girard, Pascal</creatorcontrib><creatorcontrib>Khandelwal, Akash</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley Online Library Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>CPT: pharmacometrics and systems pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wilkins, Justin J.</au><au>Brockhaus, Brigitte</au><au>Dai, Haiqing</au><au>Vugmeyster, Yulia</au><au>White, Joleen T.</au><au>Brar, Satjit</au><au>Bello, Carlo L.</au><au>Neuteboom, Berend</au><au>Wade, Janet R.</au><au>Girard, Pascal</au><au>Khandelwal, Akash</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma</atitle><jtitle>CPT: pharmacometrics and systems pharmacology</jtitle><addtitle>CPT Pharmacometrics Syst Pharmacol</addtitle><date>2019-06</date><risdate>2019</risdate><volume>8</volume><issue>6</issue><spage>415</spage><epage>427</epage><pages>415-427</pages><issn>2163-8306</issn><eissn>2163-8306</eissn><abstract>Avelumab, a human anti–programmed death ligand 1 immunoglobulin G1 antibody, has shown efficacy and manageable safety in multiple tumors. A two‐compartment population pharmacokinetic model for avelumab incorporating intrinsic and extrinsic covariates and time‐varying clearance (CL) was identified based on data from 1,827 patients across three clinical studies. Of 14 tumor types, a decrease in CL over time was more notable in metastatic Merkel cell carcinoma and squamous cell carcinoma of the head and neck, which had maximum decreases of 32.1% and 24.7%, respectively. The magnitude of reduction in CL was higher in responders than in nonresponders. Significant covariate effects of baseline weight, baseline albumin, and sex were identified on both CL and central distribution volume. Significant covariate effects of black/African American race, C‐reactive protein, and immunogenicity were found on CL. None of the covariate or time‐dependent effects were clinically important or warranted dose adjustment.</abstract><cop>United States</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>30980481</pmid><doi>10.1002/psp4.12406</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-7099-9396</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2163-8306
ispartof CPT: pharmacometrics and systems pharmacology, 2019-06, Vol.8 (6), p.415-427
issn 2163-8306
2163-8306
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_15698363073445438b2f4a3bd6accacf
source Open Access: PubMed Central; Publicly Available Content Database; Wiley Open Access
subjects Bladder cancer
Clinical trials
Employees
Gastric cancer
Immunoglobulins
Immunotherapy
Medical prognosis
Metastasis
Monoclonal antibodies
Pharmacokinetics
Population
Skin cancer
Targeted cancer therapy
Tumors
title Time‐Varying Clearance and Impact of Disease State on the Pharmacokinetics of Avelumab in Merkel Cell Carcinoma and Urothelial Carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T22%3A53%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Time%E2%80%90Varying%20Clearance%20and%20Impact%20of%20Disease%20State%20on%20the%20Pharmacokinetics%20of%20Avelumab%20in%20Merkel%20Cell%20Carcinoma%20and%20Urothelial%20Carcinoma&rft.jtitle=CPT:%20pharmacometrics%20and%20systems%20pharmacology&rft.au=Wilkins,%20Justin%20J.&rft.date=2019-06&rft.volume=8&rft.issue=6&rft.spage=415&rft.epage=427&rft.pages=415-427&rft.issn=2163-8306&rft.eissn=2163-8306&rft_id=info:doi/10.1002/psp4.12406&rft_dat=%3Cproquest_doaj_%3E2265775722%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5146-d56cb5067121bbcd2aecd687a8d709065d81ae33dc73245e387a748342e36e503%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2265775722&rft_id=info:pmid/30980481&rfr_iscdi=true